BioNTech Provides Strategic Business Update and Outlines 2026 Areas of Focus at 44th Annual J.P. Morgan Healthcare Conference

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

• BioNTech anticipates a modest decline in Comirnaty revenues compared to 2025, reflecting COVID-19 vaccine market dynamics

  80% confidence

• BioNTech has more than doubled the number of Phase 2 and 3 oncology trials across key modalities within the past two years, with now more than 25 Phase 2 or 3 trials ongoing

  80% confidence

• BioNTech does not currently anticipate the recognition of revenues from the sale of any oncology products in 2026

  80% confidence

• 2026 is poised to be a catalyst-rich year for BioNTech with continued late-stage pipeline progress with candidates across immunomodulators, antibody-drug conjugates and mRNA immunotherapies

  80% confidence

• BioNTech plans to initiate six additional Phase 3 clinical trials in 2026, bringing the total number of anticipated Phase 3 clinical trials to 15 by year end

  80% confidence

• Revenues to BioNTech from the collaboration with BMS in 2026 are expected to be broadly in line with 2025

  80% confidence

• BioNTech expects at least 17 late-stage data readouts, including from pivotal trials, by 2030+

  80% confidence

• BioNTech expects seven late-stage data readouts in 2026

  80% confidence

• BioNTech has more than ten novel-novel combination clinical trials in its pipeline with multiple data updates expected in 2026

  80% confidence

• 2026 will be a year when science translates into tangible results with readouts from late-stage trials and earlier trials evaluating novel-novel combinations

  80% confidence

Data points we hold from this source